

Curriculum Vitae- Erika Cecchin

Name: Erika Cecchin



Current job: Clinical and research pharmacologist –
Experimental and Clinical Pharmacology Unit - CENTRO DI
RIFERIMENTO ONCOLOGICO- National Cancer Center di Aviano (since
2005)

Institute address: via Franco Gallini, 2- 33081- Aviano (PN)- Italy

Education/Training

2023- University of Milan, Italy; Specialization in Clinical Pharmacology and Toxicology; “Impact of *DPYD**9A, *DPYD* C.496A>G, *DPYD**6, and related haplotypes on the development of severe toxicity to fluoropyrimidines in patients enrolled in the U-PGX/ PREPARE prospective randomized clinical study”

2006- University of Padova, Italy; PhD in Medicinal Sciences; “Pharmacogenetics markers of toxicity and response to chemotherapy in advanced colorectal cancer patients, first line treated with an irinotecan-based regimen”

2000- University of Padova, Italy; Degree in Medicinal Chemistry and Technology Pharmaceutical sciences

1998 -Chemistry Department of the University of Wales, Bangor (U.K.) Stage in Synthesis of nucleic acid base derived for ring opening metathesis polymerization

Positions

Since 2024- Centro di Riferimento Oncologico (National Cancer Institute) Experimental and Clinical Pharmacology, Sostituto Direttore di SOC

2006-2024 Centro di Riferimento Oncologico (National Cancer Institute) Experimental and Clinical Pharmacology, directed by Dr. Giuseppe Toffoli Aviano, Italy PharmD, Resident Pharmacologist-Supervisor Pharmacogenomics Laboratory

2002-2005 Centro di Riferimento Oncologico (National Cancer Institute) Experimental and Clinical Pharmacology, directed by Giuseppe Toffoli Aviano, Italy Research fellow

2001-2002 University of Padova Medicinal Chemistry Department, directed by Prof Manlio Palumbo -Padova, Italy -Research fellow

2000 Istituto Nazionale Tumori (National Cancer Institute)-Experimental Oncology, directed by Dr. Nadia Zaffaroni - Milan, Italy -Research fellow

2000 Professional training in community pharmacy “Dr. Borsatti”, Pordenone

Other professional affiliations

-Member of the Academic Board of the School of Doctorate in PERSONALIZED MEDICINE AND INNOVATIVE THERAPIES, University of Trieste (since 2025)

-Contract Professor School of Clinical Pharmacology and Toxicology, University of Trieste (since 2024)

-Member of the Academic Board of the School of Clinical Pharmacology and Toxicology, University of Trieste (since 2024)

-Member of the Academic Board of the School of Doctorate in Molecular Medicine, University of Udine (since 2017)

-Qualification to the profession of Pharmacist (University of Padova, 2001)

-Registration in the Register of Pharmacists of Pordenone (since 2005)

-Member of the Scientific Committee of PharmaDIAGEN, pharmacogenetic spin-off, (2009 - 2015).

-Member of the Independent Ethical Committee of the CRO in Aviano as an expert in Pharmacology (2014- 2016)

-Pharmacogenetics Assessor for EMQN (European Molecular Genetics Quality Network) (2019-

Editorial Boards/ Scientific Societies

- Member of Executive Board of European Society of Pharmacogenomics and Personalized Medicine (ESPT) (since 2024)

- Vice-Chair Pharmacogenetic Working Group of International Association for the International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDM-CT) (since 2023)

- Pharmacogenomic Section Member of International Union of Basic and Clinical Pharmacology (IUPHAR) (since 2017)

- Pharmacogenomic Working Group Member of Italian Society of Pharmacology (SIF)- (since 2014)

-Member of Ubiquitous Pharmacogenomics Consortium (www.upgx.eu) (since 2015)

-Academic Editor for *PlosONE*, *World Journal of Gastroenterology*, *World Cancer Research Journal*, *The Pharmacogenomics Journal*

- Guest Editor of Special Issue on “Pharmacogenomics and Personalized Medicine” for *Genes* (IF 3.600)
- Guest Editor of a Special Issue on “Advances and Challenges in Pharmacogenomics” for *Journal of Clinical Medicine* (IF 5.583)

Awards and Honors:

2010: awarded with the 'Guido Berlucchi Foundation' prize for young researchers

2009: winner of Start-Cup FVG 2009 -innovation prize- as co-founder of Spin-Off Pharmadiagen

Research Grants

- Principal Investigator. ‘Farmacogenetica, Monitoraggio Terapeutico dei farmaci (TDM) e Farmacovigilanza attiva quali strumenti innovativi finalizzati all'ottimizzazione/appropriatezza della terapia farmacologica e alla minimizzazione dei rischi di ADRs nella pratica clinica: un approccio multidisciplinare esportabile a livello nazionale’. Fondi AIFA 2015-2016-2017, (quota del 20% del fondo residuo disponibile per i progetti regionali in applicazione dell’Accordo Stato Regioni 9 giugno 2019 (punto 7.3)
- Principal Investigator. POR FESR 2014-2020. Attività 1.3.b. DGR n. 849/2016. Pratica n. 24195/2016 “Integrated platform for anti-tumor FARMAcological therapy of PReclsione and Cost-Effective - FARMAPRICE”
- Associated Investigator. Ricerca Finalizzata RF-2021-12374355. “Development of a multiparametric model based on host and tumor immune-related features for predicting complete pathological response to neoadjuvant chemoradiation in locally advanced rectal cancer.”
- Associated Investigator. CEE Anno 2016 H2020- U-PGx grant agreement n. 668353-2 “European Union’s Horizon 2020 research and innovation programme” No 668353
- Associated Investigator. Ricerca Finalizzata NET-2013-02355002 “Thalidomide, a novel immunological treatment to modify the natural history of paediatric Crohn's disease: a new proposal from a well-established paediatric research network”

Teaching activity

- Anno accademico 2024/2025: Materia: “Introduzione alla farmacogenetica e applicazione nel controllo dei costi di gestione delle tossicità” (titolo del corso: Corso di Perfezionamento in Farmacoeconomia e Terapia Personalizzata) - Ente organizzatore: Università Degli Studi di Padova (indirizzo: Via 8 Febbraio, 2 - 35122 Padova) -N. 2,00 ore di docenza
- Anno accademico 2023/2024: Incarico per attività di insegnamento (Art.23, L. 240/2010) – SSM24-54 – BIOMARCATORI DI TOSSICITA' E RISPOSTA AI FARMACI 1- Didattica curriculare DSM – Scuole di Specializzazione Mediche- Università degli Studi di Trieste (6 ore)

• Anno accademico 2023/2024: Materia: Farmacogenetica e Farmacogenomica: basi della terapia personalizzata (titolo del corso: Corso di laurea in CTF e Farmacia dell'Università degli Studi di Padova) - Ente organizzatore: Università Degli Studi di Padova Facoltà di Farmacia (indirizzo: Via 8 Febbraio, 2 - 35122 Padova) - N.4,00 ore di docenza

• Anno accademico 2023/2024: Materia: Applicazione della farmacogenomica nell'ottimizzazione dei costi di gestione delle tossicità (titolo del corso: Corso di Perfezionamento in Farmacoeconomia e Terapia Personalizzata) - Ente organizzatore: Università Degli Studi di Padova (indirizzo: Via 8 Febbraio, 2 - 35122 Padova) -N. 2,00 ore di docenza

• Anno accademico 2022/2023: Materia: Applicazione della farmacogenomica nell'ottimizzazione dei costi di gestione delle tossicità (titolo del corso: Corso di Perfezionamento in Farmacoeconomia e Terapia Personalizzata) - Ente organizzatore: Università degli Studi di Padova (indirizzo: Via 8 Febbraio, 2 - 35122 Padova) -N. 2,00 ore di docenza

• Anno accademico 2019/2020: Materia: Farmacogenetica e Farmacogenomica: basi della terapia personalizzata (titolo del corso: Farmacogenetica dei chemioterapici antitumorali) - Ente organizzatore: Università Degli Studi di Padova Facoltà di Farmacia (indirizzo: Via 8 Febbraio, 2 - 35122 Padova) - N. 4,00 ore di docenza

• Anno accademico 2013/2014: Materia: La diagnostica farmacogenetica per la personalizzazione della terapia farmacologica nel tumore colon-rettale (titolo del corso: Short Course in Diagnostica Molecolare) - Ente organizzatore: Università Degli Studi di Padova- Facoltà di Farmacia (indirizzo: Via 8 Febbraio, 2 – 35122 Padova) - N. 2,00 ore di docenza

• Anno accademico 2014/2015: Materia: Pharmacogenomics of cancer treatment (titolo del corso: Summer School in Pharmacogenomics - From Research to Clinic) – Ente organizzatore: University of Ljubljana Facoltà di Medicina (indirizzo: Kongresni trg 12, 1000 Ljubljana, Slovenia) - N. 6,00 ore di docenza

• Anno accademico 2015/2016: Materia: Clinical implementation of host pharmacogenomics: focus on colorectal cancer (titolo del corso: Summer School-Genomic Medicine Bridging research and the clinic) - Ente organizzatore: University of Ljubljana Facoltà di Medicina (indirizzo: Kongresni trg 12, 1000 Ljubljana, Slovenia) - N. 6,00 ore di docenza

Supervisor or co-supervisor of Master's degree Theses:

2025	M Gambron, Master's degree course in Pharmacy, University of Trieste
2024	AC Pisano, Master's degree course in Biotechnology, University of Trieste
2023	B Franco, Master's degree course in Chemistry and Pharmaceutical Sciences, University of Trieste
2023	E Crosara, Master's degree course in Biotechnology, University of Trieste
2023	MA Pavan, Master's degree course in Pharmacy, University of Trieste
2022	M Zinato, "Personalized therapy for oral anticancer drugs: an integrated approach based on therapeutic drug monitoring and pharmacogenetics for sunitinib and imatinib" Master's degree course in Pharmacy, University of Padova
2022	S Nuzzo, "CDK4/6 inhibitors in metastatic breast cancer: Pharmacogenetics of ADME genes to predict differences in toxicity and treatment schedule adherence", Master's degree course in Pharmacy, University of Padova
2021	E Peruzzi, "Implementation of a pharmacogenetic panel as a predictive tool to toxicity outcome in the treatment of CDK4/6 inhibitors" Master's degree course in Pharmacy, University of Padova
2019	R Borsatti, "Monitoraggio terapeutico di pazienti affetti da Tumore Stromale Gastrointestinale (GIST) mediante sequenziamento del DNA circolante e quantificazione delle concentrazioni plasmatiche di imatinib" Master's degree course in Pharmacy, University of Trieste
2018	S Mezzalana, "FARMAPRICE. Development of a computerized support platform for the prescribing process based on pharmacogenetics for personalized drug therapy" Master's degree course in Pharmacy, University of Padova
2017	C Dalle Fratte, "DPYD c.1236 / HAPB3: predictive role and clinical validity in the management of fluoropyrimidine toxicity and relative impact on costs for the national health system" Master's degree course in Pharmacy, University of Padova
2013	F Lo Re, "La farmacogenetica dei miRNA nella terapia personalizzata del cancro", Master's degree course in Pharmacy, University of Padova
2012	G Della Flora, "selezione di marcatori farmacogenetici associati ai miRNA per la personalizzazione della terapia farmacologica anti-tumorale", Master's degree course in Chemistry and Pharmaceutical Sciences, University of Trieste
2011	F Ciot, "Farmacogenetica dei recettori nucleari in pazienti con carcinoma del colon retto trattati con regime FOLFIRI", Master's degree course in Chemistry and Pharmaceutical Sciences, University of Padova
2010	E Dreussi, "Nuovi approcci molecolari e bioinformatici per l'identificazione di potenziali marcatori farmacogenetici di risposta alla chemio-radioterapia

neoadiuvante in pazienti con carcinoma del retto localmente avanzato”, Master's degree course in Biotechnology, University of Trieste

- 2008** C Zanusso, “Nuovi approcci per la caratterizzazione farmacogenetica ed epigenetica delle glutathione S-transferasi nella personalizzazione della terapia adiuvante del carcinoma colonrettale basata sulla somministrazione di oxaliplatino”, Master's degree course in Chemistry and Pharmaceutical Sciences, University of Padova
- 2006** L Italia, “Ruolo di alcuni polimorfismi di UGT1A1, UGT1A7, UGT1A9 e aplotipi correlati, nella tossicità e risposta alla chemioterapia basata sull'irinotecano in pazienti con carcinoma colonrettale metastatico”, Master's degree course in Pharmacy, University of Padova
- 2005** E De Mattia, “Farmacogenetica Dei Derivati del Platino nella Chemioterapia antitumorale”, Master's degree course in Biotechnology, University of Trieste

Supervisor or co-supervisor of PhD Theses:

- 2024-** Aurora Giacomini, PhD course in Biomedical and Biothechnology Science, University of Udine
- 2023-** Eleonora Cecchin, PhD course in Biomedical and Biothechnology Science, University of Udine
- 2022-2025** N Milan, PhD course in Biomedical and Biothechnology Science, University of Udine
- 2019-2021** S Mezzalana, “Sex-specific DPYD pharmacogenomic markers of the fluoropyrimidines treatment safety and efficacy in colorectal cancer patients” PhD course in Biomedical and Biothechnology Science, University of Udine
- 2018-2020** C Dalle Fratte, “The role of liquid biopsies in monitoring pharmacoresistance in solid tumors” PhD course in Biomedical and Biothechnology Science, University of Udine
- 2017-2019** F Ecchia, “Definition of common and rare germline variants related to Fluoropyrimidines toxicity to increase anti-cancer treatment safety” PhD course in Biomedical and Biothechnology Science, University of Udine
- 2014-2017** R Roncato, “Pharmacogenetics and therapy personalization in metastatic colorectal cancer patients treated with irinotecan” PhD course in Pharmacological Sciences, University of Padova
- 2012-2015** E Dreussi, “Pharmacogenetics of microRNAs for personalized anticancer treatment” PhD course in Chemistry and Pharmaceutical Sciences, University of Trieste
- 2008-2011** E De Mattia, “Pharmacogenetics of irinotecan in association with fluoropyrimidine (FOLFIRI) in treatment of patients with metastatic colorectal carcinoma” PhD course in Pharmacological Sciences, University of Padova

Participation in national and international conferences as an invited speaker:

- “Convegno Monotematico del GdL Farmacovigilanza, Farmacoepidemiologia, Farmacoeconomia & Real World Evidence della Società Italiana di Farmacologia”. Verona, Italy, June 24, 2025.
- “European Society of Human Genetics Pharmacogenomics Course”. Portoroz, Slovenia, June 04-06, 2025.
- “European Society of Human Genetics Conference 2025”. Milano, Italy, May 24-27, 2025.
- “Life 2 Women – Il trattamento della paziente HR+ e HER2- dall’adiuvante al metastatico”. Iseo, Italy, May 23, 2025.
- “Oncologia di precisione: uno sguardo al futuro – Il CRO incontra “La Sapienza”. Aviano CRO, Italy, April 29, 2025.
- “EIT Morning Health Talks - The role of data in life sciences research: insights and perspectives”. Trieste, Italy, April 16, 2025.
- Webinar “K-SYNC Harmonizing breast cancer expertise”. Aviano CRO, Italy, 09 April, 2025.
- Webinar “Clinical implementation of pharmacogenomics in oncology”. IVPN Network, February 23, 2025.
- “Focus sul carcinoma mammario – XXII edizione”. Udine, Italy, February 20-21, 2025.
- Comitato Scientifico: “22° Congress of Therapeutic Drug Monitoring and Clinical Toxicology- IATDMCT 2024”. Banff, Canada, September 19-22, 2024.
- “42° Congresso Nazionale della Società Italiana di Farmacologia”. Sorrento, Italy, November 13- 16, 2024.
- “Training course on germline and somatic Pharmacogenetics”. Cagliari, Italy, September 12-13, 2024.
- “Congressus Pharmaceuticus Hungaricus XVII. AND EUFEPS Annual Meeting 2024”. Debrecen, Hungary, May 2024.
- Comitato Scientifico: CONVEGNO MONOTEMATICO SIF “Strategies and perspectives for the implementation of pharmacogenomics in clinical practice” Gruppo di Lavoro Farmacogenetica. Cagliari, Italy, April 11-12, 2024.
- “7th European Society of Personalized Medicine- ESPT”. Copenhagen, Denmark, October 26-28, 2023.
- “19th World Congress Of Basic & Clinical Pharmacology”. Glasgow, United Kingdom, July 3-7, 2023.
- “European Society of Human Genetics Pharmacogenetics Course”. Portoroz, Slovenia, September 22-24, 2022.
- “41° Congresso Nazionale della Società Italiana di Farmacologia”. Roma, Italy, November 16-19, 2022.
- “Le interazioni Farmacologiche”, Evento Formativo Residenziale, “La gestione pratica della paziente con carcinoma mammario hr+/her2-: un percorso condiviso”. Padova, Italy, April 5-6, 2022.
- “Implementation of pharmacogenetics in the oncological clinical practice: the experience of an Italian IRCCS- Cancer Research Center”, 19° Congress of Therapeutic Drug Monitoring and Clinical Toxicology- IATDMCT 2021. Roma, Italy, September 19-22, 2021.
- “Pharmacogenetic testing in oncology”, the 7th U-PGx Personalized Medicine Day. On-line, March 24th, 2021.

- "Pharmacogenomics to refine multi-modality treatment in locally advanced rectal cancer", 40° Congresso nazionale SIF - Societa' Italiana di farmacologia. On-line, March 8-18, 2021.
- "Pharmacogenetics Implementation in clinical practice", 39° Congresso nazionale SIF - Societa' Italiana di farmacologia. Firenze, Italy, November 20-23, 2019.
- "Farmacologia e farmacogenomica in oncologia: alle origini della target therapy", Medicina personalizzata e ruolo del farmacista clinico: management di reazioni avverse e interazioni nelle target terapie. CRO Aviano, Italy, September 26, 2019.
- "Clinical implementation of pharmacogenomic markers to increase treatment safety in oncology", 47th ESCP Symposium on Clinical Pharmacy. Belfast, Northern Ireland, October 24-26, 2018.
- "Pharmacogenomics in oncology, from discovery to clinical implementation", 5th U-PGx Personalised Medicine Day. Liverpool, United Kingdom, September 21, 2018.
- "Clinical use of PGx guided therapy-focus on oncology", UPGx Summer School- Towards Pharmacogenomics in Clinic. Bonn, Germany, August 23, 2018.
- "Analisi del profilo genetico dell'ospite per definire la risposta e la tossicità al trattamento di combinazione chemio-radioterapico neo adiuvante nel tumore del retto localmente avanzato" Nuove Frontiere in Radioterapia AIRO Lombardia meeting. Como, Italy, March 24, 2018.
- "Pharmacogenomics to increase anti-cancer drugs safety, from research to clinical implementation" 3rd U-PGx Day- Golden Helix. Toulouse, France, November 17, 2017.
- "Pharmacogenomics of Colorectal Cancer: From Discovery to Clinical Implementation and Back" EACPT Congress 2017. Prague, Repubblica Ceca, June 24-27, 2017. Cit. Clinical Therapeutics, Vol. 39, Issue 8, e102–e103- August 2017.
- "Tailoring the treatment in colorectal cancer patients: research and clinical application in the field of the host pharmacogenomics" Golden Helix Summer School. Syros, Greece, September 22-26, 2016.
- "La farmacogenomica come guida al miglior utilizzo dei farmaci citotossici e target nei tumori ovarici" Evento Formativo ECM- "Il Dipt di Ricerca Traslazionale incontra il Dpt Medico, Chirurgico e radioterapico: Nuovi approcci nei tumori femminili (Neoplasie dell'ovaio). CRO Aviano, Italy, June 28, 2016.
- "Clinical implementation of host pharmacogenomics: focus on colorectal cancer" Summer School-Genomic Medicine – Bridging research and the clinic. ". Portoroz, Slovenia, May 3-7 2016.
- "Tailoring the treatment in colorectal cancer patients: research and clinical application in the field of the host pharmacogenomics" Workshop for high school and university lecturers Pharmacogenomics - From Research to Clinic Faculty of Medicine, University of Ljubljana. Slovenia, June 8-10, 2015.
- "Tailoring the treatment in colorectal cancer patients: research and clinical application in the field of the host pharmacogenomics" Young Investigator Event. CRO Aviano, Italy, May 25-26, 2015.
- "La farmacogenetica nella gestione del paziente con tumore coloretale, l'esperienza traslazionale al CRO di Aviano" VI Congresso FITELAB 2015- Slow Medicine Laboratory: IT's the Future. Ospedale Borgo Roma , Verona, Italy, October 3-5, 2015.
- "La farmacogenetica nella gestione del paziente con tumore coloretale, l'esperienza traslazionale al CRO di Aviano" Convegno SIGN 2014- La genetica oggi in oncologia. CRO Aviano, Italy January 24, 2014.
- "Profilo Farmacogenetico dell'Ospite: Aspetti Applicativi e Prospettive" Convegno "Carcinoma del retto: approcci innovative nella personalizzazione della terapia". CRO Aviano, Italy, April 14, 2014.

- "Pharmacogenetics and prediction of toxicity: from bench to bed-side" 8th STAR NETWORK MEETING 2013. Lerici, Italy, November 2013.
- "Clinical validity of *UGT1A1**28 genotyping in the management of metastatic colorectal cancer patients: the CRO translational experience". 36° Congresso SIF. Torino, Italy, October 2013.
- "Carcinoma del retto: caratterizzazione farmacogenetica" Convegno: "Società Italiana Tumori- il carcinoma del retto". CRO Aviano, Italy, May 27, 2011.
- La sindrome post-finasteride "valutazione farmacogenetica di pazienti con sindrome post-finasteride". Ospedale Cattinara, Trieste, Italy, September 16, 2011.
- "Personalizzare la terapia farmacologica ovvero farmacogenetica: dalla teoria alla pratica: esperienze all'IRCCS del CRO di Aviano". Centro Congressi, Trieste, Italy, October 7 2011.
- "Genetic profiles for prediction of response to radiotherapy - From pharmacogenetics to personalized cancer therapy". Aviano CRO, Italy, December 14, 2009.

Peer-reviewed publications:

1. Guchelaar HJ, van der Wouden CH, Manson LEN, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, **Cecchin E**, Cheung KC, Deneer VHM, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila-Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Swen JJ; Ubiquitous Pharmacogenomics Consortium. **Clin Pharmacol Ther.** Pharmacogenetic Implementation Studies-Lessons Learned From the PREPARE Study. 2025 Jun 24. doi: 10.1002/cpt.3749. Online ahead of print. PMID: 40552566
2. Dal Bo M, Gambirasi M, Vruzhač I, **Cecchin E**, Pishdadian A, Toffoli G, Safa A. Targeting Aging Hallmarks with Monoclonal Antibodies: A New Era in Cancer Immunotherapy and Geriatric Medicine. **Int J Mol Sci.** 2025 May 22;26(11):4982. doi: 10.3390/ijms26114982. PMID: 40507795 Free PMC article. Review.
3. Orleni M, Gagno S, Cecchin E, Montico M, Buonadonna A, Fumagalli A, Guardascione M, Puglisi F, Toffoli G, Posocco B, **Cecchin E** Imatinib and norimatinib therapeutic monitoring using dried blood spots: Analytical and clinical validation, and performance comparison of volumetric collection devices. **J Chromatogr B Analyt Technol Biomed Life Sci.** 2025 Apr 1;1255:124526. doi: 10.1016/j.jchromb.2025.124526. Epub 2025 Feb 18. PMID: 39985852
4. Pharmacogenetic Information on Drug Labels of the Italian Agency of Medicines (AIFA): Actionability and Comparison Across Other Regulatory Agencies. Moschella A, Mourou S, Perfler S, Zoroddu E, Bezzini D, Soru D, Trignano C, Miozzo M, Squassina A, **Cecchin E**, Floris M. **Clin Transl Sci.** 2025 Feb;18(2):e70138. doi: 10.1111/cts.70138. PMID: 39910906 Free PMC article.
5. Zudeh G, Selvestrel D, Bramuzzo M, **Cecchin E**, D'Andrea M, Stankovic B, Kotur N, Zukic B, Dragasevic S, Decorti G, Stocco G, Lucafò M NLRP3 promoter methylation as a predictive biomarker for glucocorticoid response in patients with inflammatory bowel disease. **Biomed Pharmacother.** 2025 Jan 17;183:117824. doi: 10.1016/j.biopha.2025.117824.
6. Roncato R, Bignucolo A, Peruzzi E, Montico M, De Mattia E, Foltran L, Guardascione M, D'Andrea M, Favaretto A, Puglisi F, Swen JJ, Guchelaar HJ, Toffoli G, **Cecchin E**. Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial. **JAMA Netw Open.** 2024 Dec 2;7(12):e2449441. doi: 10.1001/jamanetworkopen.2024.49441.
7. De Mattia E, Polesel J, Scarabel L and **Cecchin E** (2024) Clinical implications of a gain-of function genetic polymorphism in DPYD (rs4294451) in colorectal cancer patients treated with fluoropyrimidines. **Front. Pharmacol.** 15:1516375. doi: 10.3389/fphar.2024.1516375
8. Gagno S, Posocco B, Orleni M, Cecchin Ele, Fumagalli A, Guardascione M, Buonadonna A, Polesel J, Puglisi F, Toffoli G, **Cecchin E**. Increased plasma imatinib exposure and toxicity in chronically treated GIST patients with SARS-CoV-2 infection: a case series. **Front Immunol.** 2024 Oct 9;15:1441620. doi: 10.3389/fimmu.2024.1441620. eCollection 2024. PMID: 39445010. **IMPACT FACTOR**
9. Cecchin Ele, Orleni M, Gagno S, Montico M, Peruzzi E, Roncato R, Gerratana L, Corsetti S, Puglisi F, Toffoli G, **Cecchin E**, Posocco B. Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring. **Int J Mol Sci.** 2024 Sep 27;25(19):10453. doi: 10.3390/ijms251910453. PMID: 39408783. **IMPACT FACTOR**
10. Elena Peruzzi, Bianca Posocco, Lorenzo Gerratana, Margherita Nuti1, Marco Orleni, Sara Gagno, Elena De Mattia, Fabio Puglisi, **Erika Cecchin**, Giuseppe Toffoli and Rossana Roncato. Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug-gene interactions. **Front. Pharmacol.** 2024. 15:1420174. doi: 10.3389/fphar.2024.1420174. **IMPACT FACTOR**
11. Roncato, R., Polesel, J., Tosi, F., Peruzzi, E., Brugugnoli, E., Pantano, C.L., Furfaro, M., Girolamo, F.D., Nani, A., Pani, A., Milan, N., Mattia, E.D., Sartore-Bianchi, A., **Cecchin, E.** The challenge of molecular selection in liver-limited metastatic colorectal cancer for surgical resection: a systematic review and meta-analysis in the context of current and future approaches (2024) **Oncology Research**, 32 (9), pp. 1407-1422. **IMPACT FACTOR**

12. De Mattia, E., Milan, N., Assaraf, Y.G., Toffoli, G., **Cecchin, E.** Clinical Implementation of Rare and Novel DPYD Variants for Personalizing Fluoropyrimidine Treatment: Challenges and Opportunities (2024) **International Journal of Biological Sciences**, 20 (10), pp. 3742-3759. **IMPACT FACTOR**
13. Milan, N., Navarria, F., **Cecchin, E#**, De Mattia, E. Somatic pharmacogenomics in the treatment prognosis of locally advanced rectal cancer patients: a narrative review of the literature (2024) **Expert Review of Clinical Pharmacology**, 17 (8), pp. 683-719. **IMPACT FACTOR**
14. Elena Peruzzi, Rossana Roncato, Elena De Mattia, Alessia Bignucolo, Jesse J Swen, Henk-Jan Guchelaar, Giuseppe Toffoli, **Erika Cecchin**. Implementation of preemptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? **Br J Clin Pharmacol**. 2023 Nov 5. doi: 10.1111/bcp.15956. Online ahead of print. **IMPACT FACTOR 3.716**
15. Elena De Mattia, Jerry Polesel, Marco Silvestri, Rossana Roncato, Lucia Scarabel, Stefano Calza, Michele Spina, Fabio Puglisi, Giuseppe Toffoli and Erika Cecchin. The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity. *Human Genomics* (2023) 17:99; <https://doi.org/10.1186/s40246-023-00546-9>
16. Sara Gagno, Chiara Dalle Fratte, Bianca Posocco, Angela Buonadonna, Arianna Fumagalli, Michela Guardascione, Giuseppe Toffoli, **Erika Cecchin**. Therapeutic drug monitoring and pharmacogenetics to tune imatinib exposure in gastrointestinal stromal tumor patients: hurdles and perspectives for clinical implementation. **Pharmacogenomics**. 2023 Nov 13. doi: 10.2217/pgs-2023-0198. Online ahead of print. **IMPACT FACTOR 2.800**
17. Vasileios Fragoulakis, Rossana Roncato, Alessia Bignucolo, GP. Patrinos, G Toffoli, **E Cecchin**, C Mitropoulou, Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study. **Pharmacol Res**. 2023 Oct 5;197:106949. doi: 10.1016/j.phrs.2023.106949. Online ahead of print. PMID: 37802427 **IMPACT FACTOR 10.334**
18. Peruzzi E, Gerratana L, Montico M, Posocco B, Corsetti S, Bartoletti M, Gagno S, Orleni M, De Mattia E, Baraldo M, **Cecchin E**, Puglisi F, Toffoli G, Roncato R. Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer. **Biomed Pharmacother**. 2023 Sep 19;167:115479. doi: 10.1016/j.biopha.2023.115479. Online ahead of print. **IMPACT FACTOR 7.180**
19. Maurizio Polano, Luca Bedon, Michele Dal Bo, Roberto Sorio, Michele Bartoletti, Elena De Mattia, **Erika Cecchin**, Carmela Pisano, Domenica Lorusso, Andrea Alberto Lissoni, Andrea De Censi, Sabrina Chiara Cecere, Paolo Scollo, Sergio Marchini, Laura Arenare, Ugo De Giorgi, Daniela Califano, Elena Biagioli, Paolo Chiodini, Francesco Perrone, Sandro Pignata, Giuseppe Toffoli. Machine Learning Application Identifies Germline Markers of Hypertension in Ovarian Cancer Patients Treated with Carboplatin, Taxane and Bevacizumab. **Clin Pharmacol Ther**, 2023. May 27. doi: 10.1002/cpt.2960. Online ahead of print. **IMPACT FACTOR 7.051**
20. Sara Gagno, Angela Buonadonna, Chiara Dalle Fratte, Michela Guardascione, Martina Zanchetta, Bianca Posocco, Marco Orleni, Giovanni Canil, Rossana Roncato, **Erika Cecchin**, Giuseppe Toffoli. The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure. **DARU Journal of Pharmaceutical Sciences**, 2023 <https://doi.org/10.1007/s40199-023-00465-z>. **IMPACT FACTOR 4.088**
21. Rossana Roncato, Elena Peruzzi, Lorenzo Gerratana, Bianca Posocco, Sofia Nuzzo, Marcella Montico, Marco Orleni, Serena Corsetti, Michele Bartoletti, Sara Gagno, Giovanni Canil, Elena De Mattia, Jacopo Angelini, Massimo Baraldo, Fabio Puglisi, **Erika Cecchin#**, and Giuseppe Toffoli. Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure. **Biomed Pharmacother**. 2023. *Accepted*. **IMPACT FACTOR 7.180**
22. **Erika Cecchin**, Bianca Posocco, Silvia Mezzalana, Marialuisa Appetecchia, Giuseppe Toffoli; The role of gender pharmacogenetics in the personalization of drug treatment. **J Pharmacol Exp Ther**. 2023 Mar 31; JPET-MR-2022-001416. doi: 10.1124/jpet.122.001416. Online ahead of print. **IMPACT FACTOR 4.404**
23. de With M, Sadlon A, **Cecchin E**, Haufroid V, Thomas F, Joerger M, van Schaik RHN, Mathijssen RHJ, Largiadè CR; 'The Working Group on the Implementation of DPD-deficiency Testing in Europe'. Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe. **ESMO Open**. 2023 Mar 27;8(2):101197. doi: 10.1016/j.esmoop.2023.101197. Online ahead of print PMID: 36989883. **IMPACT FACTOR 6.883**

24. Elena De Mattia, Jerry Polesel, Silvia Mezzalana, Elisa Palazzari, Sara Pollesel, Giuseppe Toffoli and **Erika Cecchin**. Predictive and Prognostic Value of Oncogene Mutations and Microsatellite Instability in Locally-Advanced Rectal Cancer Treated with Neoadjuvant Radiation-Based Therapy. 2023. Accepted. **Cancers. IMPACT FACTOR 6.126**
25. Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure. An Original Work and Meta-Analysis. Chiara Dalle Fratte, Jerry Polesel, Sara Gagno, Bianca Posocco, Elena De Mattia, Rossana Roncato, Marco Orleni, Fabio Puglisi, Michela Guardascione, Angela Buonadonna, Giuseppe Toffoli and **Erika Cecchin**. 2023. Accepted **Int J Mol Science. IMPACT FACTOR 5.542**
26. Scarabel L, Polesel J, De Mattia E, Buonadonna A, D'Andrea MR, **Cecchin E**, Toffoli G Association of HLA-G 3'UTR Polymorphisms with Response to First-Line FOLFIRI Treatment in Metastatic Colorectal Cancer. *Pharmaceutics*. 2022 Dec 7;14(12):2737. doi: 10.3390/pharmaceutics14122737. **IMPACT FACTOR 6.190**
27. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster randomised crossover implementation study. Jesse J Swen, Cathelijne H van der Wouden*, Lisanne EN Manson*, Heshu Abdullah-Koolmees, Kathrin Blagec, Tanja Blagus, Stefan Böhringer, Anne Cambon-Thomsen, **Erika Cecchin**, Ka-Chun Cheung, Vera HM Deneer, Mathilde Dupui, Magnus Ingelman-Sundberg, Siv Jonsson, Candace Joefield-Roka, Katja S Just, Mats O Karlsson, Lidija Konta, Rudolf Koopmann, Marjolein Kriek, Thorsten Lehr, Christina Mitropoulou, Emmanuelle Rial-Sebbag, Victoria Rollinson, Rossana Roncato, Matthias Samwald, Elke Schaeffeler, Maria Skokou, Matthias Schwab, Daniela Steinberger, Julia C Stingl, Roman Tremmel, Richard M Turner, Mandy H van Rhenen, Cristina L Dávila Fajardo, Vita Dolžan, George P Patrinos, Munir Pirmohamed, Gere Sunder-Plassmann, Giuseppe Toffoli, Henk-Jan Guchelaar, on behalf of the Ubiquitous Pharmacogenomics Consortium. **The Lancet**. 2023 401: 347–56. **IMPACT FACTOR 202.7**
28. DNA methylation of the TPMT gene and azathioprine pharmacokinetics in children with very early onset inflammatory bowel disease. Selvestrel D, Stocco G, Aloï M, Arrigo S, Cardile S, **Cecchin E**, Congia M, Curci D, Gatti S, Graziano F, Langefeld CD, Lucafò M, Martellosi S, Martinelli M, Pagarin S, Scarallo L, Stacul EF, Strisciuglio C, Thompson S, Zuin G, Decorti G, Bramuzzo M. **Biomed Pharmacother**. 2022 Nov 30;157:113901. doi: 10.1016/j.biopha.2022.113901. **IMPACT FACTOR 7.180**
29. Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC. Scarabel L, Bignucolo A, Toffoli G, **Cecchin E**, De Mattia E. **Pharmaceutics**. 2022 Nov 15;14(11):2468. doi: 10.3390/pharmaceutics14112468. **IMPACT FACTOR 6.072**
30. Dalle Fratte C, Gagno S, Roncato R, Polesel J, Zanchetta M, Buzzo M, Posocco B, De Mattia E, Borsatti R, Puglisi F, Foltran L, Guardascione M, Buonadonna A, **Cecchin E**, Toffoli G. CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients. **Br J Clin Pharm**, 2022. doi: 10.1111/bcp.15551. **IMPACT FACTOR 3.38**
31. De Mattia E, Silvestri M, Polesel J, Ecça F, Mezzalana S, Scarabel L, Zhou Y, Roncato R, Lauschke VM, Calza S, Spina M, Puglisi F, Toffoli G, **Cecchin E**. Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk. **Biomed Pharmacother**. 2022 Sep 2; 154:113644. doi: 10.1016/j.biopha.2022.113644. Online ahead of print. PMID: 36063648. **IMPACT FACTOR 7.180**
32. Roncato R, Gerratana L, Palmero L, Gagno S, Poetto AS, Peruzzi E, Zanchetta M, Posocco B, De Mattia E, Canil G, Alberti M, Orleni M, Toffoli G, Puglisi F, **Cecchin E**. An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer. **Front Pharmacol**. 2022 Jul 22;13:897951. doi: 10.3389/fphar.2022.897951. eCollection 2022.PMID: 35942220. **IMPACT FACTOR 5.988**
33. Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers. Bignucolo A, Scarabel L, Toffoli G, **Cecchin E**, De Mattia E. **Expert Rev Clin Pharmacol**. 2022 Jun;15(6):689-713. doi: 10.1080/17512433.2022.2101447. Epub 2022 Jul 21.PMID: 35829762 **IMPACT FACTOR 3.456**
34. Blagec K, Koopmann R, Crommentuijn – van Rhenen M, Holsappel I, van der Wouden CH, Konta L, Xu H, Ott S, Steinberger D, Swen JJ, **Cecchin E**, Dolžan V, Dávila Fajardo CL, Patrinos GP, Sunder-Plassmann G, Turner R, Guchelaar HJ, Samwald M Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries. **PlosOne**. 2022 PLoS ONE 17(6): e0268534. <https://doi.org/10.1371/journal.pone.0268534>. **IMPACT FACTOR 3.240**
35. Vianello C, Cocetta V, Catanzaro D, Dorn GW 2nd, De Milito A, Rizzolio F, Canzonieri V, **Cecchin E**, Roncato R, Toffoli G, Quagliariello V, Di Mauro A, Losito S, Maurea N, Cono S, Sales G, Scorrano L,

- Giacomello M, Montopoli M. Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy. **Cell Death Dis.** 2022 Apr 22;13(4):398. doi: 10.1038/s41419-022-04741-9. IMPACT FACTOR 8.469
36. Luca Bedon, **Erika Cecchin**, Emanuele Fabbiani, Michele Dal Bo, Angela Buonadonna, Maurizio Polano and Giuseppe Toffoli. Machine Learning Application in a Phase I Clinical Trial Allows to Identify Clinical-Biomolecular Markers Significantly Associated with Toxicity. **Clin Pharmacol Ther**, 2022. 111(3), 686-696 doi:10.1002/cpt.2511. IMPACT FACTOR 6.875
 37. Elena De Mattia, Vincenzo Canzonieri, Jerry Polesel, Silvia Mezzalana, Chiara Dalle Fratte, Eva Dreussi, Rossana Roncato, Alessia Bignucolo, Roberto Innocente, Claudio Belluco, Salvatore Pucciarelli, Antonino De Paoli, Elisa Palazzari, Giuseppe Toffoli, and **Erika Cecchin**. SMAD3 host and tumor profiling to identify locally advanced rectal cancer patients at high risk of poor response to neoadjuvant chemoradiotherapy. **Frontiers in Pharmacology**, 2021 Dec 24;12:778781. doi: 10.3389/fphar.2021.778781. eCollection 2021. IMPACT FACTOR 5.330
 38. Karas S, Etheridge AS, Nickerson DA, Cox NJ, Mohlke KL, **Cecchin E**, Toffoli G, Mathijssen RHJ, Forrest A, Bies RR, Innocenti F. Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients. **Br J Cancer.** 2022 Mar;126(4):640-651. doi: 10.1038/s41416-021-01589-2. PMID: 34703007 IMPACT FACTOR 5.791
 39. Alessia Bignucolo, Scarabel Lucia, Mezzalana Silvia, Jerry Polesel, **Erika Cecchin**, Giuseppe Toffoli. Sex disparities in efficacy in COVID-19 vaccines: a systematic review and meta-analysis. **Vaccines (Basel).** 2021 Jul 27;9(8):825. doi: 10.3390/vaccines9080825. PMID: **34451950**. IMPACT FACTOR 3.143
 40. Sabrina Angelini, **Erika Cecchin**, Valeria Conti, Fabrizio Dal Piaz, Amelia Filippelli, Patrizia Hrelia, Ida Landini, Pierantonio Menna, Enrico Mini, Stefania Nobili, Ariana Soledad Poetto, Gloria Ravegnini, Rossana Roncato, Giorgio Minotti. Therapeutic drug monitoring for the cancer patient: challenges and opportunity. **Pharmadvances**. 2021 Accepted
 41. R. Roncato, **E. Cecchin**, C. Dalle Fratte, G. Decorti, M. Del Re, R. Franca, S. Nobili, G. Ravegnini, G. Stocco, E. Mini, G. Toffoli, Cancer Pharmacology Working Group of the Italian Society of Pharmacology (CPWG-SIF). Cancer pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers. **Pharmadvances**. 2021 Accepted.
 42. Chiara Dalle Fratte; Silvia Mezzalana; Jerry Polesel; Elena De Mattia; Antonio Palumbo, Angela Buonadonna; Elisa Palazzari; Antonino De Paoli; Claudio Belluco, Vincenzo Canzonieri, Giuseppe Toffoli; and **Erika Cecchin**. A panel of tumor biomarkers to predict complete pathological response to neo-adjuvant treatment in Locally Advanced Rectal Cancer. **Oncology Research**. 2022 Jan 31;28(9):847-855. doi: 10.3727/096504021X16232280278813. Epub 2021 Jun 9. PMID: 34108073. IMPACT FACTOR 4.949
 43. De Mattia E, Polesel J, Roncato R, Labriet A, Bignucolo A, Gagno S, Buonadonna A, D'Andrea M, Lévesque E, Jonker D, Couture F, Guillemette C, **Cecchin E**, Toffoli G. IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm. **Cancers**. 2021 Apr 3;13(7):1705. doi: 10.3390/cancers13071705. IMPACT FACTOR 6.126
 44. Sara Gagno, Michele Bartoletti, Chiara Romualdi, Elena Poletto, Simona Scalone, Roberto Sorio, Martina Zanchetta, Elena De Mattia, Rossana Roncato, Erika Cecchin, Giorgio Giorda, and Giuseppe Toffoli. Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer. **Pharmacogenomics**. 2020. 21(14), 995–1010.
 45. Rampazzo E, **Cecchin E**, Del Bianco P, Menin C, Spolverato G, Giunco S, Lonardi S, Malacrida S, De Paoli A, Toffoli G, Pucciarelli S, De Rossi A, Genetic variants of the TERT gene, telomere length, and circulating TERT as prognostic markers in rectal cancer patients. **Cancers**. 2020 Oct 25;12(11):3115. doi: 10.3390/cancers12113115. PMID: 33113831. IMPACT FACTOR 6.126
 46. Dietz S, Christopoulos P, Yuan Z, Gu L, Volckmar AL, Ogorodnik SJ, Angeles AK, Dalle Fratte C, Zemojtel T, Schneider MA, Kazdal D, Endris V, Meister M, Muley T, **Cecchin E**, Reck M, Schlesner M, Thomas M, Stenzinger A, and Sultmann H. Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. 2020. **EBioMedicine**. In press IMPACT FACTOR 5.736
 47. Roncato R, Angelini J, Pani A, **Cecchin E**, Sartore-Bianchi A, Siena S, De Mattia E, Scaglione F, and Toffoli G. CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions 2020. **Int. J. Mol. Sci. In Press** IMPACT FACTOR 4.556

48. Dal Bo M, De Mattia E, Baboci L, Mezzalana S, **Cecchin E**, Assaraf YG, Toffoli G. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. **Drug Resist Updat.** 2020; 51:100702. doi: 10.1016/j.drug.2020.100702. IMPACT FACTOR 11.708
49. M Lucafò, D Sicari, A Chicco, D Curci, A Bellazzo, A Di Silvestre, C Pegolo, R Autry, **E Cecchin**, S De Iudicibus, L Collavin, W Evans, G Decorti, G Stocco. miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway. 2020. **Cancer Chemother Pharmacol.** IMPACT FACTOR 2.967
50. **Cecchin E** and Stocco G#, Pharmacogenomics and Personalized Medicine, Editorial, **Genes** (Basel). 2020. 22;11(6):679. doi: 10.3390/genes11060679 IMPACT FACTOR: **3.191**
51. Elena De Mattia, Rossana Roncato, Elisa Palazzari, Giuseppe Toffoli and **Erika Cecchin**. Germline and somatic pharmacogenomics to refine rectal cancer patients selection for neo-adjuvant chemoradiotherapy. **Front. Pharmacol.** 2020. IMPACT FACTOR 4.400
52. **Cecchin E**#, De Mattia E, Dreussi E, Montico M, Palazzari E, Navarra F, Bergamo F, Belluco C, Quartuccio L, De Vita S, Canzonieri V, Gagno S, Zanusso C, Buonadonna A, Pucciarelli S, De Paoli A, Toffoli G. Immunogenetic markers in IL17F predict the risk of metastases spread and overall survival in rectal cancer patients treated with neoadjuvant chemoradiotherapy. **RadiotherOncol.** 2020. 149:30-37. doi: 10.1016/j.radonc.2020.04.055. IMPACT FACTOR: 5.252
53. van der Wouden CH, Böhringer S, **Cecchin E**, Cheung KC, Dávila-Fajardo CL6, Deneer VHM, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Rial-Sebbag E, Samwald M, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, van Zwet E, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. **Pharmacogenet Genomics.** 2020; 30(6):131-144. doi: 10.1097/FPC.0000000000000405. IMPACT FACTOR: 2.693
54. Gagno S, Poletto E, Bartoletti M, Quartuccio L, Romualdi C, Garziera M, Scalone S, Sorio R, Dreussi E, Zanusso C, De Mattia E, Roncato R, **Cecchin E**, Giorda G, De Vita S, Dal Bo M, Puglisi F, Toffoli G. A TGF- β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer. **Gynecol Oncol.** 2020 Jan;156(1):233-242. doi: 10.1016/j.ygyno.2019.10.019. PubMed PMID: 31711657. IMPACT FACTOR: 4.393
55. Spinel Karas, Amy Etheridge, Eleftheria Tsakalozou, Jackie Ramirez, Kelli Hammond, **Erika Cecchin**, Giuseppe Toffoli, Ron H.N. van Schaik, Mark J. Ratain, Ron H.J. Mathijssen, Alan Forrest, Robert R. Bies, Federico Innocenti. Optimal Sampling Strategies for Irinotecan (CPT-11) and Its Active Metabolite (SN-38) in Cancer Patients. **The AAPS (American Association of Pharmaceutical Scientists) Journal.** 2020, 17;22(3):59. doi: 10.1208/s12248-020-0429-4. IMPACT FACTOR: 3.845
56. Chiara Dalle Fratte, Michela Guardascione, Elena De Mattia, Eugenio Borsatti, Roberta Boschetto, Angelo Farruggio, Vincenzo Canzonieri, Loredana Romanato, Rachele Borsatti, Sara Gagno, Elena Marangon, Maurizio Polano, Angela Buonadonna, Giuseppe Toffoli, **Erika Cecchin**. Clonal selection of a novel deleterious TP53 somatic mutation discovered in ctDNA of a KIT/PDGFRA wild type Gastrointestinal Stromal Tumor resistant to imatinib. **Frontiers in Pharmacology**, section Pharmacogenetics and Pharmacogenomics. 2020, 11:36. doi: 10.3389/fphar.2020.00036. eCollection 2020. IMPACT FACTOR: 3.545
57. Silvia Mezzalana, Elena De Mattia, Michela Guardascione, Chiara Dalle Fratte, **Erika Cecchin**#, and Giuseppe Toffoli. Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients' Management and Therapy Outcomes. **Int. J. Mol. Sci.** 2019, Nov 5;20(21):5498. doi: 10.3390/ijms20215498; IMPACT FACTOR: **3.226**
58. De Mattia E, Polesel J, Roncato R, Labriet A, Bignucolo A, Dreussi E, Romanato L, Guardascione M, Buonadonna A, D'Andrea M, Lévesque E, Jonker D, Couture F, Guillemette C, **Cecchin E**#, Toffoli G. Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI. **Front Oncol.** 2019 Nov 26;9:1312. doi: 10.3389/fonc.2019.01312. PMID: 31850208; PMCID: PMC6901926. IMPACT FACTOR: 4.137
59. Labriet A, Lévesque É, De Mattia E, **Cecchin E**, Jonker D, Couture F, Simonyan D, Buonadonna A, D'Andrea M, Villeneuve L, Toffoli G, Guillemette C. Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients.

Pharmacogenomics. 2019 Nov;20(17):1179-1187. doi: 10.2217/pgs-2019-0091. Epub 2019 Nov 8. PMID: 31698983. IMPACT FACTOR: 2.265

60. Marica Garziera *, **Erika Cecchin**, Giorgio Giorda, Roberto Sorio, Simona Scalone, Elena De Mattia, Rossana Roncato, Sara Gagno, Elena Poletto, Loredana Romanato, Fabrizio Ecça, Vincenzo Canzonieri, Giuseppe Toffoli. Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC). **Cells**. 2019. 8(10):1186. doi: 10.3390/cells8101186 IMPACT FACTOR: **5.656**
61. Labriet A, Lévesque É, **Cecchin E**, De Mattia E, Villeneuve L, Rouleau M, Jonker D, Couture F, Simonyan D, Allain EP, Buonadonna A, D'Andrea M, Toffoli G, Guillemette C. Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients. **Sci Rep**. 2019 Sep 10;9(1):13008. doi: 10.1038/s41598-019-49477-3]. IMPACT FACTOR: **4.525**
62. Dugo M, Devecchi A, De Cecco L, **Cecchin E**, Mezzanzanica D, Sensi M, Bagnoli M. Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study. **Genes** (Basel). 2019 Sep 5;10(9). pii: E678. doi: 10.3390/genes1009067. IMPACT FACTOR: **3.191**
63. De Mattia E, Bignucolo A, Toffoli G, **Cecchin E**. Genetic markers of the host to predict the efficacy of colorectal cancer targeted therapy. **Curr Med Chem**. 2019. 27(25):4249-4273. doi: 10.2174/0929867326666190712151417 IMPACT FACTOR: **3.469**
64. De Mattia E, **Cecchin E**, Guardascione M, Foltran L, Di Raimo T, Angelini F, D'Andrea MR and Toffoli G. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. **World Journal of Gastroenterology** 2019. 25(29):3870-3896. doi: 10.3748/wjg.v25.i29.3870. IMPACT FACTOR: **3.365**
65. Garziera M, Roncato R, Montico M, De Mattia E, Gagno S, Poletto E, Scalone S, Canzonieri V, Giorda G, Sorio R, **Cecchin E**, and Toffoli G. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach. **Cells** 2019, 8, 584 ; doi:10.3390/cells8060584. IMPACT FACTOR: **4.829**
66. Fragoulakis V, Roncato R, Dalle Fratte C, Ecça F, Bartsakoulia M, Innocenti F, Toffoli G, **Cecchin E**, Patrinos GP, Mitropoulou C. Estimating the effectiveness of DPYD genotyping in individuals of Italian origin suffering from cancer based on the cost of chemotherapy-induced toxicity. **American Journal of Human Genetics**. 2019 May 18. pii: S0002-9297(19)30165-X. doi: 10.1016/j.ajhg.2019.04.017. [Epub ahead of print. IMPACT FACTOR: **8.855**
67. Just K, Turner R, Dolzan V, **Cecchin E**, Swen J, Gurwitz D, and Stingl J. Educating the next generation of PGx experts: global educational needs and concepts. **Clinical Pharmacology and Therapeutics**. 2019; 106(2):313-316. doi: 10.1002/cpt.1471. IMPACT FACTOR: **6.544**
68. Zanusso C, Dreussi E, Bortolus R, Romualdi C, Gagno S, De Mattia E, Romanato L, Sartor F, Quartuccio L, **Cecchin E**, Toffoli G. rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy. **Int. J. Mol. Sci**. 2019, 20(9), 2082; IMPACT FACTOR:**3.226**
69. Roncato R, Dal Cin L, Mezzalana S, Comello F, De Mattia E, Bignucolo A, Giollo L, D'Errico S, Gulotta A, Emili L, Carbone V, Guardascione M, Foltran L, Toffoli G, **Cecchin E**. FARMAPRICE: a pharmacogenetic Clinical Decision Support System for precise and cost-effective therapy. **Genes** 2019; 10, 276; doi:10.3390/genes10040276 IMPACT FACTOR: 3.191
70. Lucafò M, Stocco, Martelossi S, Favretto D, Franca R, Malusà N, Lora A, Bramuzzo M, Naviglio S, **Cecchin E**, Toffoli G, Ventura A, Decorti G. Azathioprine biotransformation in young patients with inflammatory bowel disease: contribution of glutathione-S transferase M1 and A1 variants. **Genes** 2019; 10, 277; doi:10.3390/genes10040277 IMPACT FACTOR: 3.191
71. De Mattia E, Roncato R, Dalle Fratte C, Ecça F, Toffoli G, **Cecchin E**. The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines. **Cancer Drug Resistance**. 2019;2:116-30. DOI: 10.20517/cdr.2019.04
72. Gagno S, D'Andrea MR, Mansutti M, Zanusso C, Puglisi F, Dreussi E, Montico M, Biason P, **Cecchin E**, Iacono D, Russo S, Cinausero M, Saracchini S, Gasparini G, Sartori D, Bari M, Collovà E, Meo R, Merkabaoui G, Spagnoletti I, Pellegrino A, Gianni L, Sandri P, Cretella E, Vattemi E, Rocca A, Serra P, Fabbri MA, Benedetti G, Foghini L, Medici M, Basso U, Amoroso V, Riccardi F, Baldelli AM, Clerico M, Bonura S, Saggia C, Innocenti F, Toffoli G. New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a

Prospective Study. **Clinical Breast Cancer**. 2019 Apr;19(2):137-145.e4. doi: 10.1016/j.clbc.2018.11.009. IMPACT FACTOR: 2.703

73. Toffoli G, Innocenti F, Polesel J, De Mattia E, Sartor F, Dalle Fratte C, Ecça F, Dreussi E, Palazzari E, Guardascione M¹, Buonadonna A, Foltran L, Garziera M, Bignucolo A, Nobili S, Mini E, Favaretto A, Berretta M, D'Andrea M, De Paoli A, Roncato R and **Cecchin E**, The genotype for *DPYD* risk variants in colorectal cancer patients and the related toxicity management costs in clinical practice. **Clinical Pharmacology and Therapeutics**. 2019 Apr; 105(4):994-1002. doi: 10.1002/cpt.1257. IMPACT FACTOR: 6.544
74. Dalle Fratte C, Polesel J, Roncato R, De Mattia E, Ecça F, Bignucolo A, Garziera M, Dreussi E, Palazzari E, Buonadonna A, Guardascione M, Berretta M, Foltran L, Sartor F, D'Andrea M, Favaretto A, Mini E, Nobili S, De Paoli A, Toffoli G, **Cecchin E**, *DPYD* Gene Activity Score Predicts Dose-Limiting Toxicity in Fluoropyrimidine-Treated Colorectal Cancer Patients. **J Mol Clin Med**. 2018, Volume 1 Issue 3 pp. 143-150 DOI: 10.31083/j.jmcm.2018.03.003
75. De Mattia E, Dreussi E, Montico M, Gagno S, Zanusso C, Quartuccio L, De Vita S, Guardascione M, Buonadonna A, D'Andrea M, Pella N, Favaretto A, Mini E, Nobili S, **Cecchin E**, Toffoli G, A clinical-genetic score to identify surgically resected colorectal cancer patients benefiting from an adjuvant fluoropyrimidine-based therapy, 2018, **Frontiers in Pharmacology**, 9:1101, IMPACT FACTOR: 4.418
76. Lunenburg CATC, Henricks LM, Dreussi E, Peters FP, Fiocco M, Meulendijks D, Toffoli G, Guchelaar HJ, Swen JJ, **Cecchin E**, Schellens JHM, Gelderblom H. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk for severe toxicity in *DPYD* variant carriers. 2018, **European Journal of Cancer**, 104:210-218. IMPACT FACTOR: 7.19
77. **Cecchin E**, De Mattia E, Ecça F, and Toffoli G. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. 2018, **Drug Resistance Updates**, 39:18-40. IMPACT FACTOR:10.91
78. Garziera M, **Cecchin E**, Canzonieri V, Sorio R, Giorda G, Scalone S, De Mattia E, Roncato R, Gagno S, Poletto E, Romanato L, Sartor F, Polesel J, and Toffoli G. Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS). **2018 International Journal of Molecular Sciences. Open Access Journal**. 2018, 19, 1510; doi:10.3390/ijms19051510. IMPACT FACTOR:3.226
79. De Mattia E#, **Cecchin E**#, Montico M, Labriet A, Guillemette C, Dreussi E, Roncato R, Bignucolo A, Buonadonna A, D'Andrea M, Coppola L, Lonardi S, Lévesque E, Jonker D, Couture F, and Toffoli G. Association of STAT-3 rs1053004 and VDRrs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. **2018 Frontiers in Pharmacology** 9:367. IMPACT FACTOR: 4.418
80. Roncato R, **Cecchin E**, Toffoli G. "Improving Decision Making on *DPYD* and *UGT1A1**28 patients' profiling with an innovative reimbursement strategy". **2018 Mar;19(4):301-304 Pharmacogenomics**. IMPACT FACTOR: 2.35
81. Labriet A, De Mattia E, **Cecchin E**, Lévesque É, Jonker D, Couture F, Buonadonna A, D'Andrea M, Villeneuve L, Toffoli G and Guillemette C. Improved Progression-Free Survival in Metastatic Colorectal Cancer Patients Carriers of the *HNF1A* Coding Variant p.I27L Treated with Irinotecan. **2017 Frontiers in Pharmacology** 8:712. IMPACT FACTOR: 4.418
82. De Mattia E, **Cecchin E**, Polesel J, Bignucolo A, Roncato R, Lupo F, Crovatto M, Buonadonna A, Tiribelli C, Toffoli G. Genetic biomarkers for hepatocellular cancer risk in a Caucasian population. **World Journal of Gastroenterology**. 2017 September 28; 23(36): 0000-0000 IMPACT FACTOR:3.365
83. Bignucolo A, De Mattia E*, **Cecchin E**, Roncato R, Toffoli G, Pharmacogenomics of targeted agents for personalization of colorectal cancer treatment. **International Journal of Molecular Sciences. Open Access Journal**. 2017 Jul 14;18(7) IMPACT FACTOR:3.226
84. Garziera M, Virdone S, De Mattia E, Scarabel L, **Cecchin E**, Polesel J, D'Andrea M, Pella N, Buonadonna A, Favaretto A, Toffoli G. HLA-G polymorphisms predict drug-induced G3-4 toxicity related to FOLFOX chemotherapy in non-metastatic CRC. **International Journal of Molecular Sciences. Open Access Journal**. 2017 Jun 27;18(7) IMPACT FACTOR:3.226
85. Toffoli M, Dreussi E, **Cecchin E**, Valente M, Sanvilli N, Montico M, Gagno S, Garziera M, Polano M, Savarese M, Calandra-Buonaura G, Placidi F, Terzaghi M, Toffoli G, and Gigli GL. SNCA 3'UTR genetic variants in patients with Parkinson's disease and REM sleep behavior disorder. **Neurological Sciences (NEUS)**. 2017 Jul;38(7):1233-1240 *Open Access Journal*

86. De Mattia E, **Cecchin E**, Polesel J, Lupo F, Tiribelli C, Crovatto M, Buonadonna A, Toffoli G. UGT1A polymorphisms as genetic biomarkers for HCC risk in Caucasian population. **Liver International**. 2017;37:1345–1353. IMPACT FACTOR: 4.47
87. Zanusso C, Dreussi E, Bortolus R, Polesel J, Montico M, **Cecchin E**, Gagno S, Rizzolio F, Arcicasa M, Novara G, and Toffoli G. Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer. **Oncotarget**. 2017 Apr 4;8(14):22863-22875 IMPACT FACTOR: 5.008
88. Roncato R, **Cecchin E**, Montico M, De Mattia E, Giodini L, Buonadonna A, Solfrini V, Innocenti F, and Toffoli G. Cost evaluation of irinotecan-related toxicities associated with the UGT1A1*28 patient genotype **Clinical Pharmacology and Therapeutics**. 2017; 102(1):123-130. IMPACT FACTOR: 7.903
89. **Cecchin E**; Roncato R; Guchelaar HJ; Toffoli G; and on behalf of Ubiquitous Pharmacogenomics Consortium: "Ubiquitous Pharmacogenomics (U-PGX): the time for implementation is now. An Horizon2020 program to drive pharmacogenomics into clinical practice". **Current Pharmaceutical Biotechnology**. 2017 Mar; 18(3): 204-9 IMPACT FACTOR: 2.511
90. van der Wouden CH, Cambon-Thomsen A, **Cecchin E**, Cheung K, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ on behalf of the Ubiquitous Pharmacogenomics Consortium: "Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium". **Clinical Pharmacology and Therapeutics**. 2017 Mar;101(3):341-358 IMPACT FACTOR: 7.903
91. Cauci S; Chiriaco G; **Cecchin E**; Toffoli G; Xodo S; Stinco G; Trombetta C: "Androgen receptor (AR) gene (CAG)_n and (GGN)_n length polymorphisms and symptoms in young males with long-lasting adverse effects after finasteride use against androgenic alopecia". **Sexual Medicine**. 2017 Mar;5(1):e61-e71. IMPACT FACTOR: 1.188
92. De Mattia E, **Cecchin E**, Roncato R, Toffoli G: "Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine". **Pharmacogenomics**;17(14):1547-71; 2016 IMPACT FACTOR: 2.710
93. Dreussi E, **Cecchin E**, Polesel J, Canzonieri V, Agostini M, Boso C, Belluco C, Buonadonna A, Lonardi S, Bergamo F, Gagno S, Mattia E, Pucciarelli S, De Paoli A, and Toffoli G: "Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients". **Int. J. Mol. Sci.**;17:1482; 2016 IMPACT FACTOR: 3.257
94. Cesaratto L, Coan M, Grisard E, Zandonà L, De Mattia E, Poletto E, **Cecchin E**, Puglisi F, Canzonieri V, Mucignat MT, Zucchetto A, Stocco G, Colombatti A, Nicoloso MS, and Spizzo R "BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress". **Cell Death & Disease**. 7:e2374; 2016 IMPACT FACTOR: 5.177
95. Bagnoli M, Canevari S, Califano D, Losito S, Maio MD, Raspagliesi F, Carcangiu ML, Toffoli G, **Cecchin E**, Sorio R, Canzonieri V, Russo D, Scognamiglio G, Chiappetta G, Baldassarre G, Lorusso D, Scambia G, Zannoni GF, Savarese A, Carosi M, Scillo P, Breda E, Murgia V, Perrone F, Pignata S, De Cecco L, Mezzanzanica D, Multicentre Italian Trials in Ovarian cancer (MITO) translational group: "Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study". **Lancet Oncol**; 17(8):1137-46. 2016 IMPACT FACTOR: 24.725
96. Dreussi E, Pucciarelli S, De Paoli A, Polesel J, Canzonieri V, Agostini M, Friso ML, Belluco C, Buonadonna A, Lonardi S, Zanusso C, De Mattia E, Toffoli G, **Cecchin E**: "Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients". **Oncotarget**; 7(15):19781-93. 2016. IMPACT FACTOR: 5.008
97. Garziera M, Catamo E, Crovella S, Montico M, **Cecchin E**, Lonardi S, Mini E, Nobili S, Romanato L, Toffoli G: "Association of the HLA-G 3' UTR polymorphisms with colorectal cancer in Italy: a first insight". **Int J Immunogenet** ;43(1):32-9. 2016 IMPACT FACTOR: 1.247
98. **Cecchin E**, De Mattia E, Toffoli G: "Nuclear receptors and drug metabolism for the personalization of cancer therapy". **Expert Opinion on Drug Metabolism & Toxicology**; 12(3):291-306. 2016 IMPACT FACTOR: 2.831

99. Garziera M, Bidoli E, **Cecchin E**, Mini E, Nobili S, Lonardi S, Buonadonna A, Errante D, Pella N, D'Andrea M, De Marchi F, De Paoli A, Zanusso C, De Mattia E, Tassi R, Toffoli G: "HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment". **PLoS One**, 10(12): e0144000, 2015. IMPACT FACTOR: 3.53
100. Chen S, Villeneuve L, Jonker D, Couture F, Laverdière I, **Cecchin E**, Innocenti F, Toffoli G, Lévesque E, Guillemette C: "ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients". **Pharmacogenet Genomics**. 25(12):573-83. 2015 IMPACT FACTOR: 3.481
101. Toffoli G, Giodini L, Buonadonna A, Berretta M, De Paoli A, Scalone S, Miolo G, Mini E, Nobili S, Lonardi S, Pella N, Lo Re G, Montico M, Roncato R, Dreussi E, Gagno S and **Cecchin E**: "Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines". **Int J Cancer**; 137(12):2971-80, **2015**. IMPACT FACTOR: 5.085
102. De Mattia E, **Cecchin E**, Toffoli G Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy **Drug Resist Updat**;20:39-70; **2015**. IMPACT FACTOR: 8.82
103. **Cecchin E**, Perrone G, Nobili S, Polesel J, De Mattia E, Zanusso C, Petreni P, Lonardi S, Pella N, D'Andrea M, Errante D, Rizzolio F, Mazzei T, Landini I, Mini E, Toffoli G. "MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin" **The Pharmacogenomics J**, 15:219-225 **2015**. IMPACT FACTOR: 5.513
104. Chen S, Laverdiere I, Tourancheau A, Jonker D, Couture F, **Cecchin E**, Villeneuve L, Harvey M, Court MH, Innocenti F, Toffoli G, Lévesque E, Guillemette C. "A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients" **The Pharmacogenomics J**, 15(6):513-20, **2015** IMPACT FACTOR: 5.513
105. **Cecchin E**, De Mattia E, Mazzon G, Cauci S, Trombetta C, Toffoli G. "A pharmacogenetic survey of androgen receptor (CAG)_n and (GGN)_n polymorphisms in patients experiencing long term side effects after finasteride discontinuation" **Int J Biol Markers** 29(4):e310-6 **2014**. IMPACT FACTOR: 1.36
106. Dreussi, E.; Polesel, J.; De Paoli, A, Toffoli G, and **Cecchin E**, miRNA pharmacogenetics in colorectal cancer: first clinical insights **MINERVA BIOTECNOLOGICA** 26(2):75-85 **2014**. IMPACT FACTOR: 0.246
107. De Re V, Caggiari L, De Zorzi M, Talamini R, Racanelli V, D' Andrea M, Buonadonna A, Zagonel V, **Cecchin E**, Innocenti F, Toffoli G. "Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy" **PLoS One** 9(1):e84940 **2014**. IMPACT FACTOR: 3.53
108. Agostini M, Crotti S, Bedin C, **Cecchin E**, Maretto I, D'Angelo E, Pucciarelli S, Nitti D. Predictive response biomarkers in rectal cancer neoadjuvant treatment **Front Biosci (Schol Ed)**. 6:110-9 **2014**.
109. De Mattia E, Dreussi E, **Cecchin E**, Toffoli G. Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects? **Pharmacogenomics**. 14(16):2035-54 **2013**. IMPACT FACTOR:3.974
110. **Cecchin E**, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, De Mattia E, Polesel J, Innocenti F, and Toffoli G. "A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/ leucovorin/ oxaliplatin (FOLFOX4) regimen" **The Pharmacogenomics J**, 13, 403–409 **2013** IMPACT FACTOR: 5.513
111. De Mattia E, Toffoli G, Polesel J, D'Andrea M, Corona G, Zagonel V, Buonadonna A, Dreussi E, and **Cecchin E**. "Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment" **Pharmacogenetics and Genomics**, 23(10):549-57 **2013**. IMPACT FACTOR: 3.48
112. Lévesque, E., Bélanger, A.S., Harvey, M., Couture, F., Jonker D., Innocenti F., **Cecchin, E.**, Toffoli, G., and Guillemette, C. "Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan (FOLFIRI)-based regimens" **Journal of Pharmacology and Experimental Therapeutics**, 345(1):95-101 **2013**. IMPACT FACTOR:3.828

113. Dreussi, E., Biason, P., Toffoli, G., and **Cecchin, E.** miRNA pharmacogenomics: the new frontier for personalized medicine in cancer? **Pharmacogenomics**, 13(14), 1635-1650 **2012**. IMPACT FACTOR:3.974
114. **Cecchin E**, Agostini M, Pucciarelli S, De Paoli A, Canzonieri V, Sigon R, De Mattia E, Friso ML, Biason P, Visentin M, Nitti D, and Toffoli G: "Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy" **The Pharmacogenomics J**, 11(3):214-26 **2011**. IMPACT FACTOR: 4.306
115. Toffoli G, **Cecchin E**, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, and Innocenti F: "Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer" **J Clin Oncol** 28:866-71, **2010**. IMPACT FACTOR: 17.157
116. De Re V, Cannizzaro R, Canzonieri V, **Cecchin E**, Caggiari L, De Mattia E, Pratesi C, De Paoli P, and Toffoli G: "MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer" **Tumour Biol** 31:23-32, **2010**. IMPACT FACTOR:2.238
117. Di Francia R, Frigeri F, Berretta M, **Cecchin E**, Orlando C, Pinto A, Pinzani P: "Review: Decision criteria for rational selection of homogeneous genotyping platforms for pharmacogenomics testing in clinical diagnostics" **Clin Chem Lab Med** 48:447-459, **2010**. IMPACT FACTOR:1.888
118. Toffoli G, Biason P, Russo A, De Mattia E, **Cecchin E**, Hattinger CM, Pasello M, Alberghini M, Ferrari C, Scotlandi K, Picci P, Serra M: Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival **Clin Cancer Res** 15:3550-6, **2009**. IMPACT FACTOR: 6.488
119. **Cecchin E**, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, and Toffoli G: "Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan" **J Clin Oncol** 27:2457-65, **2009**. IMPACT FACTOR:17.157
120. De Mattia E, **Cecchin E**, and Toffoli G "Pharmacogenetics of stomach cancer therapy" **Tumori**, 7:S66-70. **2008**. IMPACT FACTOR:0.597
121. Toffoli G, and **Cecchin E**: "Clinical implications of genetic polymorphisms on stomach cancer drug therapy" **The Pharmacogenom J** 7:76-80, **2007**. IMPACT FACTOR:3.603
122. Toffoli G, and **Cecchin E**: "Pharmacogenetics and stomach cancer: an update" **Pharmacogenomics** 8:497-505, **2007**. IMPACT FACTOR:3.603
123. Toffoli G, De Mattia E, **Cecchin E**, Biason P, Masier S, Corona G: "Pharmacology of epidermal growth factor inhibitors" **Int J Biol Markers** 22:S24-39, **2007**. IMPACT FACTOR:0.966
124. Toffoli G, **Cecchin E**, Corona G, Russo A, Buonadonna A, D'Andrea M, Pasetto LM, Pessa S, Errante D, De Pangher V, Giusto M, Medici M, Gaion F, Sandri P, Galligioni E, Bonura S, Boccalon M, Biason P, and Frustaci S: "The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer" **J Clin Oncol** 24:3061-8, **2006**. IMPACT FACTOR: 11.810
125. **Cecchin E**, Corona G, and Toffoli G: "Reply to the Letter to the Editor from Chowbay et al" **Clin Cancer Res** 12:1942, **2006**. IMPACT FACTOR: 5.623
126. **Cecchin E**, Corona G, Masier S, Biason P, Cattarossi G, Frustaci S, Buonadonna A, Colussi A, and Toffoli G: "Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients" **Clin Cancer Res** 11:6901-7, **2005**. IMPACT FACTOR: 5.623
127. **Cecchin E**, Russo A, Corona G, Campagnutta E, Martella L, Boiocchi M, and Toffoli G "UGT1A1*28 polymorphism in ovarian cancer patients" **Oncol Reports** 12:457-62, **2004**. IMPACT FACTOR: 1.256
128. Libra M, Navolanic PM, Talamini R, **Cecchin E**, Sartor F, Tumolo S, Masier S, Travalì S, Boiocchi M, and Toffoli G "Thymidylate Synthase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine based chemotherapy" **BMC Cancer** 4:11, **2004**. IMPACT FACTOR:1.702
129. **Cecchin E**, Russo A, Campagnutta E, Martella L, and Toffoli G "Lack of association of CYP1B1*3 polymorphism and ovarian cancer in a Caucasian population" **Int J Biol Mark** 19:160-3, **2004**. IMPACT FACTOR:1.092

130. Toffoli G, and **Cecchin E** "Pharmacogenomics and stomach cancer" **Pharmacogenomics** 5:627-41, **2004**. IMPACT FACTOR:3.506
131. Toffoli G, and **Cecchin E** "Uridine diphosphoglucuronosyltransferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan, antifolates and fluoropyrimidines based chemotherapy", review article **J Chemother** 16:31-35, **2004**. IMPACT FACTOR:1.088
132. Toffoli G, Rossi D, Gaidano G, **Cecchin E**, Boiocchi M, and Carbone A "Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase" *Int J Biol Mark* 18:218-21, **2003**. IMPACT FACTOR:1.571
133. Toffoli G, **Cecchin E**, Corona G, and Boiocchi M "Pharmacogenetics of Irinotecan", **Curr Med Chem** 3:225-237, **2003**. IMPACT FACTOR:4.966
134. Toffoli G, and **Cecchin E** "Pharmacogenetics of stomach cancer" I **supplementi di Tumori** 2:S19-22, **2003**. IMPACT FACTOR:0.267

Book Chapters

-**Cecchin E**, Libra M, Cannavò C, Bruni B, Fulvi A, Toffoli G, and Stivala F: "Pharmacogenetics in cancer management: scenario for tailored therapy". In: "Sensitization of cancer cells for chemo/immuno/radiotherapy", Humana Press/Springer. 389-403, **2008**.

-Toffoli G, and **Cecchin E**: "Pharmacogenetics of ovarian cancer", In: Treatment of ovarian cancer. New York: Nova Biomedical Books Vol.13:1-25, **2005**.

La sottoscritta con la presente:

- autorizza il trattamento dei dati personali contenuti nel mio curriculum vitae in base all'art. 13 del D. Lgs. 196/2003 e all'art. 13 del Regolamento UE 2016/679 relativo alla protezione delle persone fisiche con riguardo al trattamento dei dati personali.
- dichiara di essere informato/a che il presente documento sarà pubblicato nel sito web dell'Istituto in apposita sezione di Amministrazione Trasparente
- dichiara che, a norma del D.P.R. n. 445/2000, le informazioni contenute nel presente curriculum vitae corrispondono al vero.

Aviano, 20 luglio 2025

Il Dichiarante
dott.ssa Erika Cecchin
firmato